logo

For the Inventor, By the Inventor

East Lyme, CT, United States of America

Robert John Maguire

This inventor holds 5 USPTO granted patents and 1 published patent application. Top assignee: Pfizer Corporation. Active years: 2003-2010.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Robert John Maguire. Retrieved from https://idiyas.com/inventor/robert-john-maguire

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 5 

% Patents Active = 20.0

Average Co-Inventor Count = 2.3

ph-index = 2

Forward Citations = 14(Granted Patents)


Location History:

  • Sandwich, GB (2003)
  • Groton, CT (US) (2005 - 2006)
  • East Lyme, CT (US) (2004 - 2010)

Company Filing History:

goldMedal5 out of 4,488 
 
Pfizer Corporation
 patents

Years Active: 2003-2010

Loading Chart...
5 patents (USPTO):Explore Patents
1. 7671043 - Cycloalkylamino acid derivatives (2010-03-02),
2. 7045653 - Pharmaceuticals (2006-05-16),
3. 6958402 - 3-(imidazolyl)-2-alkoxypropanoic acids (2005-10-25),
4. 6713496 - 3-(imidazolyl)-2-alkoxypropanoic acids (2004-03-30),
5. 6610707 - Heterocyclic compounds as inhibitors of rotomase enzymes (2003-08-26),

Title: The Innovative Contributions of Robert John Maguire

Introduction

Robert John Maguire is a notable inventor based in East Lyme, Connecticut. He has made significant contributions to the field of pharmaceuticals, holding a total of 5 patents. His work focuses on developing compounds that address critical health issues, particularly in the treatment of diseases.

Latest Patents

Maguire's latest patents include innovative compounds such as cycloalkylamino acid derivatives. This invention relates to compounds of a specific formula and their pharmaceutically acceptable salts, prodrugs, solvates, or hydrates. These compounds are particularly useful in treating hyperproliferative diseases and autoimmune diseases in mammals, especially humans. Another significant patent involves NEP inhibitors for treating cardiovascular disorders. This invention outlines preferred NEP inhibitors that can be utilized in various pharmaceutical compositions.

Career Highlights

Robert John Maguire has built a successful career at Pfizer Corporation, where he continues to contribute to groundbreaking research and development in pharmaceuticals. His expertise in creating innovative compounds has positioned him as a valuable asset in the industry.

Collaborations

Maguire has collaborated with esteemed colleagues, including David John Bull and Charlotte Moira Norfor Allerton. These partnerships have fostered a collaborative environment that enhances the innovation process.

Conclusion

Robert John Maguire's contributions to the field of pharmaceuticals through his patents and collaborations highlight his commitment to advancing medical science. His work continues to impact the treatment of various diseases, showcasing the importance of innovation in healthcare.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…